Reagan-Udall Foundation

Reagan-Udall Foundation
TypeResearch
FocusStaffing, regulatory science
MethodPartnerships between public and private organizations

The Reagan-Udall Foundation for the Food and Drug Administration is a private nonprofit (501c3) organization, created to support the mission of the U.S. Food and Drug Administration (FDA) to help equip FDA staff with the highest caliber, regulatory science and technology in order to enhance the safety and effectiveness of FDA regulated products. Although it was mandated by Congress in the Food and Drug Administration Amendments Act of 2007 to help support and promote FDA's regulatory science priorities, it is independent of the agency, with its own Board of Directors, staff and research agenda. The Reagan-Udall Foundation creates public–private partnerships to advance research in regulatory science, enhance medical decision making, and promote innovation. It also advances regulatory science through fellowships and other training programs, both for private scientists and for FDA staff.

Activities

The Reagan-Udall Foundation collaborates with FDA in several high-priority scientific areas identified as part of the agency's innovation strategy. These include food safety, novel approaches in the development of therapies to fight tuberculosis, and methodologies for post-market product surveillance under a program called Innovation in Medical Evidence Development and Surveillance (IMEDS).[1]

In addition to the FDA's annual funding of $1,250,000, notable recent donors to the foundation include:[2][3][4]

Past activities and projects

Three specific examples:

1) Funded by the Bill & Melinda Gates Foundation, the Reagan-Udall Foundation was an active participant in the Critical Path to TB Drug Regiments (CPTR), a global initiative co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance in March 2010 to accelerate the development of new tuberculosis (TB) treatment regimens. The Foundation's role was to convene and facilitate collaboration and dialogue between the CPTR team and a broad range of international TB stakeholders including regulatory and academic scientists, drug developers, advocates, and other NGOs, to identify, prioritize and work toward resolving regulatory science issues and challenges.

2) Funded by the Susan G. Komen for the Cure, the Reagan-Udall Foundation convened a Systems Toxicology Project with the ultimate goal of directly identifying common biological intermediates for toxicity in two classes of oncology drugs, then correlating them to an adverse event. This could enable future research within the drug class to mitigate toxic effects through dosing modification, alternative treatments, or potentially develop a new regulatory tool that would assist in future drug safety evaluation. By having an independent, third party convener, like the Reagan-Udall Foundation, multiple companies can be readily involved, along with toxicologists, oncologists and other scientists from the FDA, National Institutes of Health and academia.

3) In March 2020, at the request of the FDA, the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, created the COVID-19 Evidence Accelerator — a forum for stakeholders across the health care spectrum to share real-world data and to generate ideas on how to deal with COVID-19.

Leadership

The Reagan-Udall Foundation is managed by Susan C. Winckler, RPh, Esq., chief executive officer, and overseen by a board that includes representatives from patient/consumer advocacy groups, academic research institutions, medical product and food industries, health care providers, and at large representatives with relevant expertise and experience.[5] As required by statute, two leading government scientists - the Commissioner of the FDA and the Director of the National Institutes of Health are ex officio members of the Board. The FDA Foundation has numerous provisions in place to protect against conflicts and undue influence. Board members are prohibited from participating in matters in which they have a financial interest and must disclose their financial interest in entities doing business with the Foundation and in entities regulated by the FDA. Additionally, conflicts protections are required for each individual project the Foundation undertakes. All projects are reviewed by the Board of Directors and are subject to an independent review.

Finally, the Foundation is prohibited from participating in regulatory matters or offering advice to FDA on policy matters.

See also

References

  1. ↑ "Innovation in Medical Evidence Development and Surveillance". IMEDS program website at RUF. 2017-03-29. Archived from the original on 2019-03-02. Retrieved 2019-03-01.
  2. ↑ "2021 Annual Report". Reagan-Udall Foundation. 2021. Archived from the original on 2022-07-12. Retrieved 2022-07-12.
  3. ↑ Winckler, Susan C. "Annual Report 2020" (PDF). Reagan-Udall Foundation. Archived (PDF) from the original on 2022-07-12. Retrieved 2022-10-08.
  4. ↑ Sigal, Ellen V. "Advancing Collaboration: Annual Report 2019" (PDF). Reagan-Udall Foundation. Archived (PDF) from the original on 2022-07-12. Retrieved 2022-10-08.
  5. ↑ "FDA Announces Board Members of Reagan-Udall Foundation". Fda.gov. Retrieved 2011-05-17.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.